

Ublituximab-xiiy (Briumvi®)

Along with this order form, please include the following: Demographics, Insurance Information, Lab Results, Current Medications, and Recent Visit Notes. ArrIVE Infusion will obtain any necessary medication authorizations for patients receiving infusion therapies.

Order Date: ____/____/____

Referral Status: ☐ New Referral ☐ Dose or Frequency Change ☐ Renewal

Patient Name: _____ Patient Address: _____ Patient Phone Number: _____ Date of Birth: ____/____/____ Weight: ____ kg Height: ____ cm Allergies: _____		Primary Insurance: _____ Member ID: _____ Secondary Insurance: _____ Member ID: _____			
Diagnosis <input type="checkbox"/> Multiple Sclerosis (G35) <input type="checkbox"/> Relapsing Forms of Multiple Sclerosis (G35.11) <input type="checkbox"/> Secondary Progressive Multiple Sclerosis (G35.3) <input type="checkbox"/> Other Diagnosis Code (ICD-10): _____ <input type="checkbox"/> Other Indication: _____ Target start date: _____		Labs <input type="checkbox"/> CBC with/diff <input type="checkbox"/> Immunoglobulin IgM <input type="checkbox"/> Immunoglobulin IgG <input type="checkbox"/> HCG <input type="checkbox"/> Other: _____			
Date of Negative Hepatitis Screen: _____					
Hold and notify provider: Patient has signs/symptoms of an active infection (WBC greater than ULN, ANC greater than ULN, etc) or positive pregnancy test.					
Ublituximab-xiiy (Briumvi®) in sodium chloride 0.9% 250 mL IVPB <table border="0"> <tr> <td> Dose: <input type="checkbox"/> 150 mg <input type="checkbox"/> 450 mg <input type="checkbox"/> Other: _____ </td> <td> Frequency : <input type="checkbox"/> Induction Dose 150 mg IV followed by 450 mg IV 2 weeks later <input type="checkbox"/> Maintenance Dose: every 24 weeks <input type="checkbox"/> Other: _____ </td> </tr> </table>				Dose: <input type="checkbox"/> 150 mg <input type="checkbox"/> 450 mg <input type="checkbox"/> Other: _____	Frequency : <input type="checkbox"/> Induction Dose 150 mg IV followed by 450 mg IV 2 weeks later <input type="checkbox"/> Maintenance Dose: every 24 weeks <input type="checkbox"/> Other: _____
Dose: <input type="checkbox"/> 150 mg <input type="checkbox"/> 450 mg <input type="checkbox"/> Other: _____	Frequency : <input type="checkbox"/> Induction Dose 150 mg IV followed by 450 mg IV 2 weeks later <input type="checkbox"/> Maintenance Dose: every 24 weeks <input type="checkbox"/> Other: _____				
Pre-Medications and Pre-Protocol (ordered at physician discretion)	<input type="checkbox"/> Acetaminophen 650 mg PO once <input type="checkbox"/> Loratadine 10 mg PO once <input type="checkbox"/> Diphenhydramine once <input type="checkbox"/> 25 mg <input type="checkbox"/> 50 mg <input type="checkbox"/> PO <input type="checkbox"/> IV <input type="checkbox"/> Famotidine 20 mg IV once <input type="checkbox"/> Hydrocortisone 100 mg IV once <input type="checkbox"/> Methylprednisolone 125 mg IVP once <input type="checkbox"/> Other: _____	Hydration <input type="checkbox"/> LR <input type="checkbox"/> Sodium Chloride 0.9% <input type="checkbox"/> Other: _____ _____ mL at _____ mL/hr <input type="checkbox"/> Before <input type="checkbox"/> During <input type="checkbox"/> Following			

Flushing Protocol <i>as needed for line care</i>	<input type="checkbox"/> Sodium Chloride 0.9% <input type="checkbox"/> 5 mL <input type="checkbox"/> 10 mL	Heparin 100 Units/mL <input type="checkbox"/> 5 mL <input type="checkbox"/> 10 mL
Hypersensitivity Panel Together Care Hypersensitivity Panel will be ordered to provide emergency supportive care medication therapy as necessary	<ul style="list-style-type: none"> • Sodium chloride 0.9% bolus 500 mL once as needed for hypotensive management (SBP <90mmHg) • Acetaminophen 650 mg once as needed for temperature GREATER than 38 C (100.4 F), headaches, generalized pain, back pain, abdominal cramping • Albuterol 2.5 mg /3 mL (0.083%) nebulizer solution 2.5 mg, nebulize every 10 min PRN, hypoxemia, bronchospasm, wheezing, dyspnea, for 2 doses • Albuterol HFA inhaler 2 puffs q4hs as needed for hypoxemia, bronchospasm, wheezing, dyspnea • Epinephrine injection 0.3 mg IM every 15 minutes as needed for SBP less than 90mmHg, mild to moderate anaphylaxis for 3 doses • Famotidine injection 20 mg IV over 2 minutes once as needed for severe hypersensitivity/infusion reaction including systolic BP 80-90 mmHg, bradycardia or tachycardia, hypoxemia, dyspnea, cognitive changes, generalized rash, chest pain/pressure • Diphenhydramine injection 25 mg IV over 1 minute once as needed, moderate hypersensitivity/infusion reaction (grade 2) including temperature greater than 100.5, rigors, localized rash/hives, vomiting, nausea, pruritis, flushing, dizziness, back pain, abdominal cramping, uneasiness, agitation, feeling of impending doom • Diphenhydramine injection 50 mg IV over 1 minute once as needed for severe hypersensitivity/infusion reaction (grade 3), including systolic BP 80-90 mmHg, bradycardia or tachycardia, hypoxemia, dyspnea, cognitive changes, generalized rash, chest pain/pressure • Hydrocortisone sodium succinate injection 100 mg IV once as needed for severe hypersensitivity/infusion reaction (grade 3), including systolic BP 80-90 mmHg, bradycardia or tachycardia, hypoxemia, dyspnea, cognitive changes, generalized rash, chest pain/pressure 	
<div> Provider Name: _____ <div> Provider Signature: _____ _____ _____ </div> </div> <div> Attending Physician Name: _____ <div> Provider NPI: _____ _____ _____ </div> </div> <div> Office Phone Number: _____ <div> Office Fax Number: _____ _____ _____ </div> </div> <p><i>Note: This order is valid for 12 months from date of physician signature.</i></p>		